Compile Data Set for Download or QSAR
Report error Found 326 Enz. Inhib. hit(s) with all data for entry = 11495
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620922((3R,4R)-4-(4-(6-chloro-2-((1- cyclopropyl-5-(diflu...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620916((3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-(difluoro...)
Affinity DataIC50: 0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620971((3S,4S) or (3R, 4R)-4-((R) or (S)- 4-(6-chloro-2-(...)
Affinity DataIC50: 0.0880nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620720(US20230303540, Example Ex-3.1)
Affinity DataIC50: 0.0930nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620851(US20230303540, Example Ex-5.1)
Affinity DataIC50: 0.105nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620733(1-{6-chloro-2-[(1-cyclopropyl-5- methyl-1H-pyrazol...)
Affinity DataIC50: 0.106nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620974(US20230303540, Example Ex-13.2 | US20230303540, Ex...)
Affinity DataIC50: 0.116nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620858((3S,4S) or (3R,4R) 4-(4-{2-[(5- chloro-1-cycloprop...)
Affinity DataIC50: 0.170nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620778((3R,4R) or (3S,4S) 4-(4-(6-chloro- 2-((5-chloro-1-...)
Affinity DataIC50: 0.178nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620854((3S,4S) or (3R,4R) 4-(4-(2-((1- cyclopropyl-5-meth...)
Affinity DataIC50: 0.180nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620857((3S,4S) or (3R,4R) 4-(4-{2-[(1- cyclopropyl-5-meth...)
Affinity DataIC50: 0.197nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620779((R or S) 6-chloro-N-(5-chloro-1-((S) or (R) 2,2-d...)
Affinity DataIC50: 0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620875(US20230303540, Example Ex-6.10 | 1-(6-chloro-2-{[1...)
Affinity DataIC50: 0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868(US20230303540, Example Ex-6.34 | US20230303540, Ex...)
Affinity DataIC50: 0.212nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734({8-[6-chloro-2-({1-[3-(methoxymethyl) bicyclo[1.1....)
Affinity DataIC50: 0.218nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620731(1-(6-chloro-2-{[1-(2-hydroxy-2- methylpropyl)-1H-p...)
Affinity DataIC50: 0.221nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734({8-[6-chloro-2-({1-[3-(methoxymethyl) bicyclo[1.1....)
Affinity DataIC50: 0.227nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620977((3S,4S) or (3R, 4R)-4-(4-(2-((1- (bicyclo[1.1.1]pe...)
Affinity DataIC50: 0.267nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620893((3S,4S) or (3R,4R) 4-[4-(6- chloro-2-{[5-chloro-1-...)
Affinity DataIC50: 0.270nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620719((3S,4S or 3R,4R)-N-(1- (bicyclo[1.1.1]pentan-1-yl)...)
Affinity DataIC50: 0.279nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620853((3S,4S) or (3R,4R) 4-(4-(2-((1- (2,2-(R) or (S) di...)
Affinity DataIC50: 0.310nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620884(US20230303540, Example Ex-6.22 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.322nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620887(US20230303540, Example Ex-6.23 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.323nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620904(US20230303540, Example Ex-6.42 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.352nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620894(US20230303540, Example Ex-6.36 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.381nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620751((8-syn)-3-(6-chloro-2-{[1-(2- hydroxy-2-methylprop...)
Affinity DataIC50: 0.393nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620856((3S,4S) or (3R,4R) 4-(4-(2-((5- chloro-1-cycloprop...)
Affinity DataIC50: 0.403nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620729(1-(6-chloro-2-{[1-(2-hydroxy-2- methylpropyl)-1H-p...)
Affinity DataIC50: 0.407nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620891(US20230303540, Example Ex-6.26 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.418nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620855((3S,4S) or (3R,4R) 4-(4-(2-((5- chloro-1-(2,2-(R) ...)
Affinity DataIC50: 0.420nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620756(US20230303540, Example Ex-3.43 | (3R,4R) or (3S,4S...)
Affinity DataIC50: 0.438nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620777((3R,4R) or (3S,4S) 4-(4-(6-chloro-2- ((5-chloro-1-...)
Affinity DataIC50: 0.440nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620852((3S,4S) or (3R,4R) 4-(4-(2-((1- (2,2-(R) or (S) di...)
Affinity DataIC50: 0.450nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620746((8-syn)-3-{6-chloro-2-[(1- cyclopropyl-5-methyl-1H...)
Affinity DataIC50: 0.486nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620730(1-(6-chloro-2-{[5-chloro-1-(2- hydroxy-2-methylpro...)
Affinity DataIC50: 0.488nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620919((3S,4S) or (3R,4R) 4-(4-(7- chloro-3-((1-(2,2- dif...)
Affinity DataIC50: 0.522nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620964(US20230303540, Example Ex-12.5 | US20230303540, Ex...)
Affinity DataIC50: 0.560nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620716(US20230303540, Example Ex-2.2 | US20230303540, Exa...)
Affinity DataIC50: 0.576nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620753(6-chloro-N-{1-[3-(methoxymethyl) bicyclo[1.1.1]pen...)
Affinity DataIC50: 0.594nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620890((3S,4S) or (3R,4R) 4-(4-{6- chloro-2-[(1,5-dimethy...)
Affinity DataIC50: 0.603nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620898(US20230303540, Example Ex-6.37 | (3S,4S) or (3R,4R...)
Affinity DataIC50: 0.608nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620943(US20230303540, Example Ex-7.21 | (4S)-4-methyl-3-(...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620818(6-chloro-N-[5-chloro-1-(1- methylcyclopropyl)-1H-p...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50584328(CHEMBL5078277 | US20230303540, Example Ex-1.48)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620813(1-(6-chloro-2-{[5-chloro-1-(1- methylcyclopropyl)-...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620780(US20230303540, Example Ex-4.2 | US20230303540, Exa...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620672(6-chloro-N-[1-(2-fluoroethyl)-5- methyl-1H-pyrazol...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620953(US20230303540, Example Ex-8.10 | (4S)-3-{2-[(3-ter...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620948(US20230303540, Example Ex-8.6 | (1R,4S) or (1S,4R)...)
Affinity DataIC50: 0.625nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 326 total ) | Next | Last >>
Jump to: